14:10 time-restricted eating

What it is

All food is eaten within a consistent, self-chosen 10-hour window each day, with about 14 hours without food, and calories are not deliberately cut. It has been studied mainly in people with metabolic syndrome, alongside their usual medicines and dietary counselling.

What the research says

Evidence is limited. In a 12-week single-arm study of 19 people with metabolic syndrome, the 10-hour window was followed by lower weight, blood pressure and atherogenic lipids, but there was no control group. A 3-month randomised trial of 108 completers with metabolic syndrome found a small HbA1c improvement (-0.10%) versus standard care alone. Across all intermittent fasting types, a 2026 Cochrane review found little to no difference in weight loss compared with regular dietary advice (low-certainty evidence), and a 2025 network meta-analysis found no weight advantage of time-restricted eating over continuous energy restriction. Pooled trials of time-restricted eating report some loss of fat-free mass.

Evidence grade: Limited evidence.

The schedule

• Pattern: daily
• Fasting hours: 14
• Eating hours: 10

Why people choose it

A 10-hour window is a smaller change than 16:8 and was studied as an add-on to usual medical care for metabolic syndrome, including in people on statins and blood-pressure medicines. In a randomised trial of 8- to 10-hour eating on top of standard care, HbA1c improved only slightly (by 0.10 percentage points) and there were no major adverse events. Pooled trials of intermittent fasting, including time-restricted eating, show no clear weight advantage over ordinary dietary advice or continuous calorie restriction.

Cautions

• people taking insulin or other glucose-lowering (antihyperglycaemic) medicines: A 2026 meta-analysis of time-restricted eating in type 2 diabetes said that for patients taking antihyperglycaemic agents, blood glucose should be closely monitored and medicines adjusted in good time, both to prevent hypoglycaemia and because moving meal times can disrupt usual dosing. It did not name specific drug classes in that passage. (Source 1)
• people on heart and blood-pressure medicines: The 10-hour studies were done alongside usual medical care, with medicines allowed and tracked; they were not tested as a replacement for treatment. (Source 2)
• people with a history of eating disorders: The Cochrane team warned its results may not apply to people with underlying eating disorders or behaviours. (Source 3)
• older adults concerned about muscle: Pooled trials show time-restricted eating reduces fat-free mass, which includes muscle. (Source 4)

What goes wrong

The same diabetes meta-analysis found time-restricted eating was associated with taking longer to fall asleep, and reported mild short-lived symptoms such as dizziness and headache. (Source 1)

• Meta-analysis, Certainty not rated.
• Size: 344 participants in 12 studies.
• Who: adults with type 2 diabetes.
• How long: varied.
• Result: Sleep latency SMD 0.74 (95% CI 0.22 to 1.26); no serious hypoglycaemic events reported.
• Funding: not stated.

Limit of this finding: The authors did not give a GRADE certainty rating. Includes non-randomised interventional studies and several eating-window lengths; by the authors' risk-of-bias assessment, 7 of the 12 studies were not at low risk of bias (of 7 RCTs, 3 low risk, 2 some concerns, 2 high; of 5 non-randomised studies, 2 high, 1 moderate, 2 low).

The incidence of other adverse effects was also low, generally limited to mild and transient symptoms, such as dizziness and headache.

A meta-analysis of 20 randomised trials found that time-restricted eating reduced fat-free mass as well as fat mass. (Source 4)

• Meta-analysis, Certainty not rated.
• Size: 1,242 participants in 20 RCTs.
• Who: adults.
• How long: varied.
• Result: Fat-free mass: TRE WMD -0.58 kg (95% CI -0.81 to -0.36); TRE plus energy restriction WMD -0.56 kg (95% CI -0.81 to -0.31)
• Funding: not stated.

Limit of this finding: Pools windows of different lengths; fat-free mass includes muscle.

Pooled results showed that TRE significantly decreased body weight, fat mass, fat-free mass, body mass index (BMI) and waist circumference (WC).

What the evidence supports

In a single-arm study of people with metabolic syndrome, most of whom took statins or blood-pressure medicines, 12 weeks of eating within a self-selected 10-hour window was followed by better cardiometabolic measures; with no control group, the change cannot be attributed to the eating window. (Source 2)

• Case series, Certainty not rated.
• Size: 19 participants.
• Who: adults with metabolic syndrome and a baseline eating window of 14 hours or more, most on a statin and/or antihypertensive.
• How long: 12 weeks.
• Result: The title reports lower weight, blood pressure and atherogenic lipids after the 12 weeks; numbers are not in the recorded abstract.
• Funding: mixed: NIH grants, and Merck, Novo Nordisk, Amgen and foundations named in the Europe PMC grant record (not checked against the paper's funding section)

Limit of this finding: Single-arm trial with no control group (recorded as case-series), not a randomised trial. Very small (19 participants).

In a single-arm, paired-sample trial, 19 participants with metabolic syndrome and a baseline mean daily eating window of ≥14 h, the majority of whom were on a statin and/or antihypertensive therapy, underwent 10 h of TRE (all dietary intake within a consistent self-selected 10 h window) for 12 weeks.

In a randomised trial, adding personalised 8- to 10-hour eating to standard care for metabolic syndrome lowered HbA1c by 0.10 percentage points more than standard care alone over 3 months. (Source 5)

• Randomized trial, Certainty not rated.
• Size: 108 completers (89% of those randomised)
• Who: adults with metabolic syndrome and raised fasting glucose or HbA1c, mean age 59, BMI 31.2, baseline eating window 14.2 hours; medicines allowed.
• How long: 3 months.
• Result: HbA1c -0.10% (95% CI -0.19% to -0.003%) vs standard care.
• Funding: National Institutes of Health.

Limit of this finding: The authors list short duration and self-reported diet as limitations; the effect is small.

Compared with SOC, TRE improved HbA1c by -0.10% (95% CI, -0.19% to -0.003%).

A meta-analysis of 12 time-restricted eating studies in type 2 diabetes found lower HbA1c and fasting glucose, and more time in range on glucose monitors. (Source 1)

• Meta-analysis, Certainty not rated.
• Size: 344 participants in 12 studies.
• Who: adults with type 2 diabetes.
• How long: varied.
• Result: HbA1c MD -0.32% (95% CI -0.47 to -0.18); fasting glucose MD -0.44 mmol/L (95% CI -0.68 to -0.19); time in range MD 8.92% (95% CI 3.94 to 13.91)
• Funding: not stated.

Limit of this finding: The authors did not give a GRADE certainty rating. Includes non-randomised interventional studies and several eating-window lengths; by the authors' risk-of-bias assessment, 7 of the 12 studies were not at low risk of bias (of 7 RCTs, 3 low risk, 2 some concerns, 2 high; of 5 non-randomised studies, 2 high, 1 moderate, 2 low).

TRE significantly reduced HbA1c (MD: -0.32%, 95% CI: -0.47 to -0.18) and fasting blood glucose (MD: -0.44 mmol/L, 95% CI: -0.68 to -0.19).

What the evidence does not support

Across 21 trials, intermittent fasting (including time-restricted feeding) produced little to no difference in percentage weight loss compared with regular dietary advice. (Source 6)

• Systematic review, Low certainty.
• Size: 1,430 participants in 21 studies (22 studies, 1,995 participants in the review)
• Who: adults with overweight or obesity.
• How long: up to 12 months.
• Result: MD -0.33% (95% CI -0.92 to 0.26)
• Funding: independent (no dedicated funding)

Limit of this finding: Pools all intermittent fasting types; not specific to 10-hour windows.

Compared to regular dietary advice, intermittent fasting may result in little to no difference in percentage from baseline weight loss (MD -0.33, 95% CI -0.92 to 0.26; 21 studies, 1430 participants; low-certainty evidence due to risk of bias).

A network meta-analysis of 99 trials found that, compared with continuous energy restriction, only alternate-day fasting (not time-restricted eating) showed a weight benefit. (Source 7)

• Meta-analysis, Moderate certainty.
• Size: 6,582 adults in 99 randomised trials.
• Who: adults, healthy or with existing health conditions.
• How long: most trials under 24 weeks.
• Result: ADF vs continuous energy restriction -1.29 kg (95% CI -1.99 to -0.59); TRE showed no weight benefit over continuous energy restriction.
• Funding: NIDDK grant P30 DK056336 listed in the Europe PMC record (not checked against the paper)

Limit of this finding: Pools time-restricted eating windows of all lengths.

Compared with continuous energy restriction, alternate day fasting was the only form of intermittent fasting diet strategy to show benefit in body weight reduction (mean difference -1.29 kg (95% CI -1.99 to -0.59), moderate certainty of evidence).

The 2026 Cochrane review found intermittent fasting may have little to no effect on adverse events compared with regular dietary advice, but the evidence is very uncertain. (Source 6)

• Systematic review, Very low certainty.
• Size: 619 participants in 7 studies.
• Who: adults with overweight or obesity.
• How long: up to 12 months.
• Result: Adverse events RR 1.45 (95% CI 0.64 to 3.28)
• Funding: independent (no dedicated funding)

Limit of this finding: Pools all intermittent fasting types.

Intermittent fasting may have little to no effect on adverse events but the evidence is very uncertain (RR 1.45, 95% CI 0.64 to 3.28; 7 studies, 619 participants; very low-certainty evidence due to risk of bias, inconsistency and imprecision).

A common belief, and what the research shows

The belief: A 10-hour eating window melts weight off better than an ordinary diet.

What the research shows: Pooled trials of intermittent fasting, including time-restricted eating, show little to no weight advantage over regular dietary advice or continuous calorie restriction; the 10-hour trials in metabolic syndrome found modest effects on top of usual care.

References

1. Diabetology & Metabolic Syndrome. Effects of time-restricted eating on people with type 2 diabetes: a systematic review and meta-analysis. 2026. DOI 10.1186/s13098-026-02138-8. Read the source
2. Cell Metabolism. Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome. 2020. PMID 31813824, DOI 10.1016/j.cmet.2019.11.004. Read the source
3. Cochrane (news release). Evidence behind intermittent fasting for weight loss fails to match hype. 2026. Read the source
4. International Journal of Behavioral Nutrition and Physical Activity. Efficiency of time-restricted eating and energy restriction on anthropometrics and body composition in adults: a systematic review and meta-analysis of randomized controlled trials. 2025. PMID 41034862, DOI 10.1186/s12966-025-01812-w. Read the source
5. Annals of Internal Medicine. Time-Restricted Eating in Adults With Metabolic Syndrome: A Randomized Controlled Trial. 2024. PMID 39348690, DOI 10.7326/M24-0859. Read the source
6. Cochrane Database of Systematic Reviews. Intermittent fasting for adults with overweight or obesity. 2026. PMID 41692034, DOI 10.1002/14651858.CD015610.pub2. Read the source
7. BMJ. Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: systematic review and network meta-analysis of randomised clinical trials. 2025. PMID 40533200, DOI 10.1136/bmj-2024-082007. Read the source